Select a drug and priority to view detailed comparison
Drug | Mechanism | Dosage | Onset | Side Effects | Cost (Monthly) |
---|---|---|---|---|---|
Azilect (Rasagiline) | Irreversible MAO-B inhibitor | 1 mg once daily | 4–6 weeks | Nausea, headache, insomnia | $250–$300 |
Selegiline | Irreversible MAO-B inhibitor | 5–10 mg daily | 2–4 weeks | Dry mouth, dizziness | $180–$220 |
Safinamide | Reversible MAO-B inhibitor + glutamate modulator | 50–100 mg daily | 3–5 weeks | Dyskinesia, nausea | $280–$340 |
Pramipexole | Dopamine D2/D3 agonist | 0.125–1.5 mg three times daily | 1–2 weeks | Sleep attacks, impulse control | $150–$190 |
Ropinirole | Dopamine D2/D3 agonist | 0.25–8 mg three times daily | 1–2 weeks | Sleepiness, dizziness | $130–$170 |
Levodopa/Carbidopa | Levodopa converted to dopamine | 100–300 mg, 3–4 times daily | Within days | Nausea, orthostatic hypotension | $30–$60 |
Entacapone | COMT inhibitor | 200 mg with levodopa | Same as levodopa | Diarrhea, orange urine | $40–$70 |
When you or a loved one is diagnosed with Parkinson’s disease, the medication maze can feel overwhelming. Azilect is the brand name for Rasagiline, a once‑daily MAO‑B inhibitor that’s meant to boost brain dopamine by slowing its breakdown. But is it the right choice, or could another drug work better for your situation? This guide lines up Azilect side‑by‑side with the most common alternatives, breaking down how they work, typical dosing, side‑effects, cost, and who benefits most.
Azilect belongs to the MAO‑B inhibitor class. By blocking the enzyme monoamine oxidase‑B, it reduces the breakdown of dopamine, helping to smooth out motor symptoms such as stiffness and tremor. The drug was approved in the US in 2006 and is taken as a 1mg tablet once daily, usually after lunch to improve absorption.
Below are the six most frequently prescribed rivals, each with distinct mechanisms:
Drug | Mechanism | Typical Dose | Onset of Benefit |
---|---|---|---|
Azilect (Rasagiline) | Irreversible MAO‑B inhibitor | 1mg once daily | 4-6 weeks |
Selegiline | Irreversible MAO‑B inhibitor | 5‑10mg daily (tablet) or 5mg/24h patch | 2-4 weeks |
Safinamide | Reversible MAO‑B inhibitor + glutamate modulator | 50‑100mg daily | 3-5 weeks |
Pramipexole | Dopamine D2/D3 agonist | 0.125‑1.5mg three times daily | 1-2 weeks |
Ropinirole | Dopamine D2/D3 agonist | 0.25‑8mg three times daily | 1-2 weeks |
Levodopa/Carbidopa | Levodopa is converted to dopamine; Carbidopa reduces peripheral conversion | 100‑300mg levodopa per dose, 3-4 times daily | Within days |
Entacapone | COMT inhibitor, prolongs levodopa effect | 200mg with each levodopa dose | Same as levodopa |
Every medication carries trade‑offs. Below is a quick look at the most reported adverse events for each drug.
For most patients, the MAO‑B inhibitors (Azilect, Selegiline, Safinamide) are gentler on the gut than dopamine agonists, but they can still interact with antidepressants or certain over‑the‑counter cough medicines.
Price varies by insurance, pharmacy, and manufacturer coupons. Approximate out‑of‑pocket monthly costs for a typical adult (no insurance) are:
Because levodopa is generic, it remains the most budget‑friendly option, but it may cause motor fluctuations sooner than MAO‑B inhibitors.
Use this short checklist to see which medication matches your priorities.
Here are three common patient stories that illustrate how the comparison plays out.
Azilect is a selective MAO‑B inhibitor, which generally does not interact with most SSRIs. However, some newer antidepressants (e.g., linezolid) can cause hypertensive crises. Always check with your doctor before mixing.
No. Rasagiline is only sold as oral tablets. If you need a patch, selegiline offers a transdermal option (Emsam).
Most patients notice mild improvements in motor symptoms after 4 to 6 weeks of consistent use.
Switching is possible, but doctors usually add rasagiline to levodopa rather than replace it because levodopa provides the strongest dopamine boost.
MAO‑B inhibitors like Azilect and selegiline carry a lower dyskinesia risk compared with levodopa‑based regimens. Safinamide can actually increase dyskinesia if used with high‑dose levodopa.
If you’re ready to discuss options with your neurologist, bring the following items to the appointment:
Having this information makes it easier for the clinician to match you with the drug that balances efficacy, safety, and cost.
Written by Neil Hirsch
View all posts by: Neil Hirsch